info@mail.ucallm.com
From Vascular Identity Loss to Fibrotic Remodeling — Empowering Comprehensive EndMT Mechanism Discovery with Validated Antibody Solutions
Endothelial-to-mesenchymal transition (EndMT) is a dynamic cellular reprogramming process in which endothelial cells progressively lose vascular characteristics and acquire mesenchymal phenotypes. This transition contributes to vascular dysfunction, extracellular matrix remodeling, fibrosis progression, tumor microenvironment regulation, and organ degeneration.
During EndMT, endothelial cells undergo coordinated molecular changes characterized by:
- Loss of endothelial lineage identity
- Activation of TGF-β/SMAD signaling pathways
- Induction of EMT-associated transcription factors
- Acquisition of mesenchymal and myofibroblast characteristics
- Enhanced extracellular matrix (ECM) production and fibrosis
EndMT plays critical roles in multiple pathological contexts, including:
- Cardiovascular fibrosis and vascular remodeling
- Kidney fibrosis and chronic kidney disease
- Pulmonary fibrosis
- Atherosclerosis and vascular aging
- Cancer-associated stromal remodeling
- Tissue injury and regeneration responses
We provide comprehensive antibody solutions for investigating EndMT progression—from early endothelial destabilization and signaling activation to transcriptional reprogramming, mesenchymal conversion, and fibrotic matrix deposition.
Validated antibodies enable researchers to characterize:
- Endothelial identity maintenance and loss
- TGF-β-driven EndMT activation
- EMT/EndMT transcriptional regulation
- Mesenchymal phenotype acquisition
- ECM remodeling and fibrosis progression
- Therapeutic intervention mechanisms
EndMT Biomarker Antibody Portfolio
—Comprehensive Solutions for Vascular Plasticity, Fibrotic Transition, and Tissue Remodeling Research
EndMT is regulated by an integrated molecular network involving endothelial markers, cytokine signaling pathways, transcriptional regulators, cytoskeletal remodeling, and extracellular matrix production.
Our antibody portfolio supports systematic profiling of major EndMT regulatory stages:
Research Focus | Representative Biomarkers | Research Applications |
Endothelial Identity & Vascular Integrity | PECAM1 (CD31), CDH5 (VE-Cadherin), VWF, ERG, EMCN | Characterization of endothelial lineage maintenance and endothelial marker loss during transition |
TGF-β/SMAD EndMT Activation Signaling | TGFB1, TGFBR1, TGFBR2, p-SMAD2 (Ser465/467), p-SMAD3 (Ser423/425), SMAD4 | Analysis of canonical EndMT induction pathways and fibrosis-associated signaling activation |
Notch Signaling | NOTCH1, Cleaved NOTCH1 (Val1744), JAG1, DLL4, HES1, HEY1 | Regulation of endothelial tip/stalk cell specification and arterial/venous fate determination |
EndMT Transcriptional Reprogramming | SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, ERG, ETS1, KLF4 | Investigation of transcriptional suppression of endothelial identity and mesenchymal gene activation |
Mesenchymal Phenotype Acquisition | VIM, CDH2, ACTA2 (α-SMA), S100A4, PDGFRB | Evaluation of endothelial conversion into fibroblast-like and myofibroblast phenotypes |
Extracellular Matrix Remodeling & Fibrosis | FN1, COL1A1, COL3A1, CTGF (CCN2), MMP2, MMP9 | Assessment of ECM deposition, matrix remodeling, and fibrotic progression |
Inflammatory & Stress-Associated Regulation | RELA (p65), NLRP3, NFE2L2 (NRF2), HIF1A, SOD2 | Investigation of inflammatory microenvironment and stress-induced EndMT responses |
Key Targets in the EndMT Regulatory Network
—Comprehensive Biomarker Coverage for Endothelial Plasticity, Mesenchymal Conversion, and Fibrotic Remodeling
EndMT is controlled by a hierarchical signaling network involving endothelial identity markers, profibrotic signaling pathways, transcriptional regulators, mesenchymal transition markers, and extracellular matrix remodeling factors.
Our validated antibody portfolio enables researchers to dissect major regulatory nodes driving EndMT progression:
Key Target | Biological Role in EndMT | Research Application |
TGF-β1 / TGFBR1 / TGFBR2 | Master profibrotic signaling axis initiating SMAD-dependent EndMT activation | Detection of EndMT induction and pathway activation |
p-SMAD2 / p-SMAD3 | Activated downstream mediators of canonical TGF-β signaling | Monitoring pathway activity and transcriptional responses |
SNAIL / SLUG | EMT-associated transcriptional repressors that suppress endothelial identity genes | Identification of early endothelial phenotype transition |
ZEB1 / ZEB2 | Transcriptional regulators promoting stable mesenchymal conversion | Characterization of advanced EndMT states |
TWIST1 | Regulates mesenchymal gene expression and cellular plasticity | Investigation of invasive and fibrotic remodeling |
CD31 / PECAM-1 | Maintains endothelial lineage identity and vascular integrity | Evaluation of endothelial marker loss |
VE-Cadherin / CDH5 | Maintains endothelial junction structure and barrier function | Analysis of endothelial junction disruption |
Vimentin / VIM | Intermediate filament marker associated with mesenchymal phenotype acquisition | Confirmation of endothelial-to-mesenchymal conversion |
α-SMA / ACTA2 | Marker of activated myofibroblast differentiation | Assessment of fibrotic phenotype development |
Fibronectin / FN1 & COL1A1 | ECM components driving matrix accumulation and fibrosis | Evaluation of downstream fibrotic remodeling |
Featured EndMT Research Antibody Panels
—Integrated Biomarker Panels for Endothelial Plasticity, Mesenchymal Transition, and Fibrotic Remodeling Analysis
EndMT is a dynamic process involving coordinated changes in endothelial identity, signaling activation, transcriptional reprogramming, mesenchymal phenotype acquisition, and extracellular matrix remodeling.
Our curated antibody panels enable researchers to systematically characterize different stages of EndMT progression, from early endothelial destabilization to advanced fibrotic transformation, supporting mechanistic studies across cardiovascular disease, organ fibrosis, cancer biology, and tissue remodeling research.
EndMT Activation Panel—Decoding Early Molecular Events Driving Endothelial Phenotypic Transition
Key Markers
TGFB1 | TGFBR1 | TGFBR2 | p-SMAD2 (Ser465/467) | p-SMAD3 (Ser423/425) | SMAD4 |
Endothelial-to-Mesenchymal Conversion Panel—CCharacterizing Acquisition of Fibroblast-Like Phenotypes
Key Markers
CD31 | VE-Cadherin | Vimentin | N-Cadherin | α-SMA | S100A4 |
Fibrosis & ECM Remodeling Panel—Evaluating Downstream Matrix Deposition and Tissue Remodeling
Key Markers
Fibronectin | COL1A1 | COL3A1 | CTGF | MMP2 | MMP9 |
Multiplex EndMT Spatial Profiling Panel—Visualizing Cellular Transition and Tissue Remodeling in Complex Microenvironments
Key Markers
Endothelial Identity | CD31 | VE-Cadherin | ERG | PECAM1 | CDH5 | ERG |
Transition State | ZEB2 | SNAIL | ZEB1 |
|
|
|
Mesenchymal/Fibrotic Phenotype | Vimentin | α-SMA | Fibronectin |
|
|
|
Why Researchers Choose Our EndMT Antibody Solutions
Validated EndMT Targets. Integrated Fibrosis Pathway Coverage. Reliable Mechanistic Insights.
Our antibody portfolio supports complete EndMT research workflows:
Research Challenge | Our Solution |
How can I identify endothelial phenotype loss? | CD31, VE-Cadherin, ERG endothelial identity markers |
How can I activate and monitor EndMT signaling? | TGF-β1, TGFBR1/2, p-SMAD2/3 pathway markers |
How can I study transcriptional reprogramming? | SNAIL, SLUG, ZEB1, TWIST1 transcription factor panel |
How can I confirm mesenchymal conversion? | Vimentin, N-Cadherin, α-SMA, S100A4 markers |
How can I evaluate fibrosis progression? | Fibronectin, Collagen I/III, CTGF ECM remodeling markers |
How can I perform spatial EndMT profiling? | Multiplex IF/IHC-compatible validated antibody solutions |
Key reference
Wang W, Li Y, Zhang Y, Ye T, Wang K, Li S, Zhang Y. SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1. Cardiovasc Diabetol. 2023 Nov 28;22(1):331.
Chen C, Wang J, Hou C, Lian W, Zhu X, Hu J, Liu C. Bushen Huoxue Yiqi formula alleviates cardiac fibrosis in ischemic heart failure through SIRT1/Notch1 pathway-mediated EndMT. Phytomedicine. 2024 Dec;135:156252.
Lovisa S, Fletcher-Sananikone E, Sugimoto H, Hensel J, Lahiri S, Hertig A, Taduri G, Lawson E, Dewar R, Revuelta I, Kato N, Wu CJ, Bassett RL Jr, Putluri N, Zeisberg M, Zeisberg EM, LeBleu VS, Kalluri R. Endothelial-to-mesenchymal transition compromises vascular integrity to induce Myc-mediated metabolic reprogramming in kidney fibrosis. Sci Signal. 2020 Jun 9;13(635):eaaz2597.
Hamczyk MR, Nevado RM, Gonzalo P, Andrés-Manzano MJ, Nogales P, Quesada V, Rosado A, Torroja C, Sánchez-Cabo F, Dopazo A, Bentzon JF, López-Otín C, Andrés V. Endothelial-to-Mesenchymal Transition Contributes to Accelerated Atherosclerosis in Hutchinson-Gilford Progeria Syndrome. Circulation. 2024 Nov 12;150(20):1612-1630.
Yang Q, Cai Y, Ma Q, Xiong A, Xu P, Zhang Z, Xu J, Zhou Y, Liu Z, Zhao D, Asara J, Li W, Shi H, Caldwell RB, Sodhi A, Huo Y. Inactivation of adenosine receptor 2A suppresses endothelial-to-mesenchymal transition and inhibits subretinal fibrosis in mice. Sci Transl Med. 2024 Mar 6;16(737):eadk3868.
Shang RY, Yang JC, Hu WG, Xiao R, Hu DS, Lin ZC, Li S, Wang NN, Zheng Y, Liu ZH, Chen YX, Wang MJ, Wang C, Jiang B, Lin GA, Li XL, Shang XZ, Yan TT, Luo GX, He WF. Artesunate attenuates skin hypertrophic scar formation by inhibiting fibroblast activation and EndMT of vascular endothelial cells. Phytomedicine. 2025 May;140:156498.
Chen Z, Chang K, Yang S, Deng R, He Y, Zhang L, Chen M, Bai D, Pi Y. Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles Reverse Endothelial-Mesenchymal Transition in Atherosclerosis. J Extracell Vesicles. 2025 Jun;14(6):e70099.